2013年9月,FDA批出1个新分子实体药品沃泰西汀(vortioxetine),商品名Brintellix,为治疗重度抑郁症药品。该药品为口服片剂,规格包括5 mg、10 mg、15mg、20 mg,由日本武田公司和丹麦灵北制药公司合作开发上市。Brintellix属于新一代抗抑郁药,用于治疗有重度抑郁症的患者。该药被认为通过2种作用机制的联合发挥作用:受体活性调节和再摄取抑制。体外研究表明,沃 In September 2013, the FDA awarded vortioxetine, a new molecular entity drug, under the trade name Brintellix for the treatment of major depressive disorder. The drug is an oral tablet, specifications include 5 mg, 10 mg, 15 mg, 20 mg, developed by the Japanese company Takeda and Dancing North Pharmaceutical Company listed. Brintellix is ​​a new generation of antidepressants used to treat patients with major depressive disorder. The drug is thought to work through a combination of two mechanisms of action: modulation of receptor activity and inhibition of reuptake. In vitro studies have shown that fertile